What are stem cell exosomes? There’s been an explosion of interest in the biomedical world around a recently characterized cell-to-cell communication system that most cells use to talk to one another, including stem cells. In fact the first patient has been successfully treated in Germany with exosomes derived from mesenchymal stem cells for refractory graft […]
What are exosomes and can they be used for therapy? Read More »
Over the years some scientists including yours truly have expressed concerns about the possibility that mutations could crop up during the reprogramming process to make induced pluripotent stem cells (IPS cells or IPSC). How concerned should we be about IPS cell mutations? A cool new paper, Bhutani, et al, in Nature Communications from a team led by
For IPS cell mutations, some reassuring new data but validation still key Read More »
A great new piece in The New Yorker by Dana Goodyear, The Stress Test, gives us a window into Charles Vacanti’s side of the STAP cell mess and includes recent quotes from him. It’s a long, fascinating look inside of STAP, the tangled and ultimately tragic scientific implosion that created and then brought down two Nature
Finally, Vacanti’s side of STAP cell implosion Read More »
Haruko Obokata was reportedly questioned by police in Japan today. The questioning relates to the STAP cell scandal that led to the retraction of two Nature papers. As first author of the papers, Obokata and other authors had reported that they could make IPSC-like cells simply via acid or other stress treatment. However, it is
Obokata questioned by police over STAP cell fiasco Read More »
Clinical research on Type I Diabetes is one of the most exciting and promising areas of stem cells and regenerative medicine for human disease. Two of the coolest companies out there in this arena have been ViaCyte and BetaLogics (owned by J&J). For more on ViaCyte see my interview with President and CEO Paul Laikind
ViaCyte on the Rise: First Diabetes Trial Data & Acquires BetaLogics IP Read More »
The patent dispute on CRISPR between UC/Jennifer Doudna and The Broad/Feng Zhang has been the subject of major attention including in a recent piece on Stanford Center for Law & Biosciences Blog. There is a lot of confusion over this important CRISPR dispute so I turned to a patent expert for their take on this via an interview
Patent expert weighs in on CRISPR dispute between UC & Broad Read More »
CRISPR is the hottest new biotechnology and the top development of 2015 according to Science Magazine. What will the new year of 2016 bring on the CRISPR front? It’s clear there will be more meetings on CRISPR ethics and policy (heck, we are having one right here at UC Davis on May 26), but what
CRISPR predictions for New Year of 2016 Read More »
A new Cell Stem Cell paper by Victoria L. Mascetti and Roger Pedersen on human-mouse chimera modeling is quite interesting and important. I really enjoyed this short paper, but I do have a reservation about one way that it is being interpreted. The authors show that human pluripotent stem cells (hPSC) including induced pluripotent stem cells
Perspectives on Pedersen Lab Human-Mouse Chimera Paper Read More »
Both before and particularly now after the big human gene editing summit in Washington, D.C. at the National Academy of Sciences, I’ve talked with patients about their views on this new technology including at last week’s World Stem Cell Summit. One of the most striking moments of the DC summit was when the mother of
Just freakin do it: patients voice impatience on CRISPR for genetic diseases Read More »
“Take a Selfie”, has become a catch phrase in pop culture. There is a preoccupation with capturing one’s own existence and key moments in pictures. Another trend is a DIY culture including taking initiative with one’s own health. When combined together we are in the midst of a larger trend in medicine where patients will
Take a medical selfie: a taste of your own medicine Read More »